NGL Fine Chem Ltd
NGL Fine Chem is engaged in the Business of Chemical substances used in manufacture of pharmaceuticals and Allopathic medicines.
Product Basket
NGL manufactures APIs for Animal drugs and derives 70-75% from export to countries in Europe, Asia Pacific, Middle East and Latin America. It has a product basket of 22 products and has more than 50% market share in top 4-5 products.
- Market Cap ₹ 739 Cr.
- Current Price ₹ 1,196
- High / Low ₹ 1,375 / 220
- Stock P/E 28.6
- Book Value ₹ 200
- Dividend Yield 0.15 %
- ROCE 15.4 %
- ROE 12.5 %
- Face Value ₹ 5.00
Pros
- Company is expected to give good quarter
Cons
- No cons found. Suggest something.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 29 | 32 | 35 | 39 | 34 | 43 | 41 | 37 | 37 | 35 | 42 | 68 | |
| 24 | 26 | 30 | 32 | 27 | 33 | 32 | 33 | 34 | 33 | 30 | 49 | |
| Operating Profit | 5 | 6 | 5 | 7 | 7 | 11 | 9 | 5 | 4 | 2 | 13 | 19 |
| OPM % | 18% | 18% | 15% | 18% | 21% | 25% | 21% | 13% | 10% | 6% | 30% | 27% |
| Other Income | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 |
| Interest | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 1 | 1 | 2 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 2 |
| Profit before tax | 6 | 4 | 5 | 7 | 6 | 10 | 8 | 3 | 3 | 1 | 12 | 19 |
| Tax % | 27% | 31% | 7% | 34% | 30% | 30% | 29% | 12% | 22% | 79% | 28% | 23% |
| Net Profit | 4 | 3 | 5 | 4 | 4 | 7 | 6 | 3 | 2 | 0 | 9 | 15 |
| EPS in Rs | 6.78 | 4.97 | 7.80 | 7.15 | 6.59 | 11.02 | 8.97 | 4.81 | 3.29 | 0.23 | 14.33 | 23.96 |
| Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes | Notes |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | TTM | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 25 | 30 | 35 | 36 | 56 | 79 | 88 | 96 | 100 | 114 | 153 | 152 | 184 | |
| 21 | 25 | 30 | 32 | 48 | 68 | 73 | 74 | 74 | 92 | 121 | 129 | 146 | |
| Operating Profit | 4 | 5 | 5 | 4 | 8 | 11 | 15 | 22 | 25 | 22 | 32 | 23 | 37 |
| OPM % | 17% | 16% | 14% | 11% | 14% | 14% | 17% | 23% | 26% | 19% | 21% | 15% | 20% |
| Other Income | 0 | 0 | 0 | 0 | 0 | -1 | 2 | 0 | 1 | 3 | 4 | 1 | 7 |
| Interest | 1 | 0 | 1 | 1 | 1 | 2 | 2 | 2 | 1 | 2 | 3 | 3 | 2 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 3 | 3 | 5 | 6 | 7 | 7 |
| Profit before tax | 3 | 4 | 4 | 2 | 4 | 7 | 13 | 18 | 23 | 18 | 28 | 14 | 35 |
| Tax % | 38% | 31% | 37% | 32% | 35% | 32% | 35% | 36% | 35% | 29% | 27% | 26% | |
| Net Profit | 2 | 3 | 2 | 1 | 3 | 5 | 8 | 11 | 15 | 13 | 20 | 11 | 26 |
| EPS in Rs | 3.17 | 4.37 | 3.92 | 1.70 | 4.71 | 7.33 | 13.48 | 18.45 | 24.10 | 20.38 | 32.58 | 17.16 | 41.81 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 5% | 10% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 18% |
| 5 Years: | 12% |
| 3 Years: | 15% |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 11% |
| 3 Years: | -7% |
| TTM: | 33% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 53% |
| 5 Years: | 38% |
| 3 Years: | 37% |
| 1 Year: | 155% |
| Return on Equity | |
|---|---|
| 10 Years: | 21% |
| 5 Years: | 21% |
| 3 Years: | 18% |
| Last Year: | 13% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Sep 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |
| Reserves | 8 | 11 | 13 | 14 | 17 | 21 | 30 | 41 | 56 | 69 | 89 | 98 | 120 |
| Borrowings | 4 | 5 | 6 | 10 | 13 | 17 | 13 | 14 | 23 | 27 | 27 | 28 | 24 |
| 5 | 7 | 9 | 10 | 14 | 15 | 21 | 19 | 20 | 31 | 23 | 26 | 44 | |
| Total Liabilities | 20 | 25 | 32 | 37 | 47 | 56 | 67 | 78 | 102 | 129 | 142 | 156 | 192 |
| 6 | 6 | 11 | 10 | 18 | 19 | 17 | 24 | 25 | 56 | 61 | 61 | 59 | |
| CWIP | 0 | 1 | 1 | 5 | 0 | 0 | 1 | 2 | 16 | 3 | 0 | 0 | 0 |
| Investments | 0 | 1 | 2 | 2 | 0 | 0 | 2 | 3 | 6 | 6 | 9 | 14 | 18 |
| 13 | 17 | 19 | 21 | 30 | 37 | 46 | 49 | 55 | 63 | 73 | 80 | 115 | |
| Total Assets | 20 | 25 | 32 | 37 | 47 | 56 | 67 | 78 | 102 | 129 | 142 | 156 | 192 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0 | 1 | 4 | 1 | -0 | -0 | 8 | 8 | 10 | 22 | 9 | 20 | |
| -1 | -2 | -6 | -4 | -3 | -4 | -3 | -10 | -10 | -21 | -10 | -20 | |
| 2 | 1 | 1 | 3 | 4 | 3 | -4 | 2 | 0 | 0 | 0 | 0 | |
| Net Cash Flow | 0 | -0 | -0 | -0 | 1 | -1 | 1 | 0 | -0 | 1 | -1 | -0 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2009 | Mar 2010 | Mar 2011 | Mar 2012 | Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROCE % | 27% | 26% | 22% | 11% | 19% | 24% | 29% | 37% | 34% | 22% | 28% | 15% |
| Debtor Days | 89 | 100 | 112 | 115 | 100 | 110 | 107 | 123 | 110 | 89 | 79 | 63 |
| Inventory Turnover | 4.28 | 3.56 | 4.37 | 4.07 | 4.22 | 4.87 | 4.45 | 4.04 | 3.86 | 3.62 | 4.11 | 3.26 |
Documents
Add documentRecent announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 12h
- Board Meeting Intimation for Notice Of The Fifth Board Meeting Of 2020-21 Pursuant To Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 1d
- Shareholding for the Period Ended December 31, 2020 13 Jan
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 12 Jan
- Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate 12 Jan
View all